A global Phase 3 clinical trial has begun testing an experimental Alzheimer’s therapy designed to target toxic tau protein buildup, a key feature of disease progression. According to Reuters, the first patient has now been dosed in the study of a monoclonal antibody intended for people in the early symptomatic stage of Alzheimer’s disease.

The trial marks an important step for researchers seeking treatments that go beyond symptom management and address one of the biological drivers of cognitive decline. Tau proteins can form harmful aggregates in the brain, and scientists have long explored whether clearing those deposits could slow the worsening of the disease.

If successful, the study could add to the limited options available for patients and families facing Alzheimer’s, which remains one of the most difficult neurodegenerative diseases to treat. Large late-stage trials are essential to determine whether promising lab and early-stage results translate into real-world benefits.

Reuters reported that the program is being run globally, reflecting both the scale of the research effort and the need for diverse patient data. Results from the trial will be closely watched by neurologists, investors, and caregivers looking for evidence that tau-focused therapies can make a meaningful difference.